je.st
news
Tag: therapies
Seattle biotechs flock to Philadelphia to talk combination therapies, partnering with big pharma
2015-06-20 02:17:46| Biotech - Topix.net
Biotech industry leaders from around the world descended on Philadelphia this week to talk about the future direction of the industry. The Biotechnology Industry Organization's 2015 International BIO Convention brought together more than 2,500 CEOs and 15,000 attendees, and Seattle's biotech scene is well-represented there.
Tags: big
talk
combination
philadelphia
Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies
2015-06-01 14:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. & BERKELEY, Calif. Studies to Evaluate the Combination of Dynavaxs SD-101 with Two Immunotherapies from Mercks Pipeline, KEYTRUDA (pembrolizumab) and MK-1966 Collaboration Includes First-in-human Study for MK-1966, a New Investigational Anti-interleukin-10 (anti-IL-10) Immunomodulator from Mercks Rapidly Growing Immuno-oncology Pipeline KENILWORTH, N.J. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orMerck Investor Relations:Justin Holko, 908-740-1879orDynavax Investor/Media Relations:Michael Ostrach, 510-665-7257 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: combination
collaboration
announce
investigating
Pharmacological Advancements In Neuroscience Drug Discovery & Pre-Clinical Studies For Fragile X Syndrome To Identify Drug Candidates For Autism Therapies Lead Biotech Sector Research
2015-04-29 03:43:56| drugdiscoveryonline Home Page
In the search for neuroscience drug discovery treatments, Alzheimer's disease and specifically autism drug candidates, a few viable therapeutic approaches have come from research on neurological conditions such as fragile X syndrome
Tags: research
lead
studies
drug
UniQure Deal Confirms Red-Hot Interest In Advanced Therapies
2015-04-08 03:15:03| Trucking - Topix.net
If there is any sign that pharma is beating the bushes to flush out promising advanced therapies, it is that Bristol-Myers For a near-term outlay of nearly $100m, Bristol-Myers gets the heart failure candidate AAV-S100A1 and three other targets. Along with Bluebird Bio , Celladon and Voyager Therapeutics, UniQure shows that gene therapy has begun a modest but noteworthy renaissance.
Tags: advanced
interest
deal
confirms
Broad Institute expands collaboration with Bayer to develop new cardiovascular therapies
2015-03-31 12:57:29| Chemicals - Topix.net
The Broad Institute of MIT and Harvard have expanded their collaboration with Bayer HealthCare to include cardiovascular genomics and drug discovery. The goal of this new part of the alliance is to leverage insights from human genetics to help create new cardiovascular therapies.
Tags: develop
institute
broad
collaboration